787585-27-7

Basic information

• Product Name: Oxirane, [[(1R)-1-(2-bromophenyl)ethoxy]methyl]-, (2R)-
• CAS NO: 787585-27-7
• Molecular Formula: C11H13BrO2
• Molecular Weight: 257.127
• Mol File: 787585-27-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Oxirane, [[(1R)-1-(2-bromophenyl)ethoxy]methyl]-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Oxirane, [[(1R)-1-(2-bromophenyl)ethoxy]methyl]-, (2R)-(787585-27-7)
• EPA Substance Registry System: Oxirane, [[(1R)-1-(2-bromophenyl)ethoxy]methyl]-, (2R)-(787585-27-7)

Safety Data

• Hazardous Substances Data: 787585-27-7(Hazardous Substances Data)

Upstream product

• 460048-01-5 R-(-)-glycidyl 3-nitrobenzenesulfonate 
• 5411-56-3 (1R)-1-(2-bromophenyl)ethan-1-ol 
• 113826-06-5 (R)-glycidyl tosylate 
• 115314-14-2 (R)-glycidyl nosylate 

Downstream Products

• 804555-44-0 methyl 3-[2-[(1R)-1-(((2R)-oxiranyl)methoxy)ethyl)phenyl]propionate 
• 1260380-28-6 C₂₇H₃₃NO₄ 
• 1260380-43-5 C₂₉H₃₇NO₄ 
• 1260380-32-2 C₂₈H₃₁ClFNO₄ 
• 787583-71-5 Encaleret 
• 1260380-31-1 C₃₂H₃₅NO₄ 
• 1260380-44-6 C₃₃H₃₇NO₄ 
• 1232829-32-1 methyl (3E)-4-(2-{(1R)-1-[(2R)-oxiran-2-ylmethoxy]ethyl}phenyl)but-3-enoate 
• 1232828-91-9 methyl (2E)-3-(2-{(1R)-1-[(2R)-oxiran-2-yl methoxy]ethyl}phenyl)prop-2-enoate 
• 804555-46-2 methyl 6-[2-[(1R)-1-(((2R)-oxiranyl)methoxy)ethyl]phenyl]hexanoate 

Relevant articles and documents

Discovery of a potent and short-acting oral calcilytic with a pulsatile secretion of parathyroid hormone

Short-acting oral calcilytics, calcium-sensing receptor (CaSR) antagonists, have been considered as alternatives for parathyroid hormone (PTH), an injectable bone anabolic drug used in the treatment of osteoporosis. Previously, we identified aminopropandi

Metabolism-guided design of short-acting calcium-sensing receptor antagonists

As part of a strategy to deliver short-acting calcium-sensing receptor (CaSR) antagonists, the metabolically labile thiomethyl functionality was incorporated into the zwitterionic amino alcohol derivative 3 with the hope of increasing human clearance through oxidative metabolism, while delivering a pharmacologically inactive sulfoxide metabolite. The effort led to the identification of thioanisoles 22 and 23 as potent and orally active CaSR antagonists with a rapid onset of action and short pharmacokinetic half-lives, which led to a rapid and transient stimulation of parathyroid hormone in a dose-dependent fashion following oral administration to rats. On the basis of the balance between target pharmacology, safety, and human disposition profiles, 22 and 23 were advanced as clinical candidates for the treatment of osteoporosis.

CaSR antagonist

A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.